154 related articles for article (PubMed ID: 29916916)
21. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
22. Early PET imaging with [68]Ga-PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence.
Uprimny C; Kroiss AS; Fritz J; Decristoforo C; Kendler D; von Guggenberg E; Nilica B; Maffey-Steffan J; di Santo G; Bektic J; Horninger W; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2017 Sep; 44(10):1647-1655. PubMed ID: 28589253
[TBL] [Abstract][Full Text] [Related]
23. Optimal Time Point for 68Ga-PSMA-11 PET/CT Imaging in the Assessment of Suspected Metastatic Prostate Cancer in the Bladder of Postprostatectomy Patient.
Xu G; Lu Y
Clin Nucl Med; 2021 Aug; 46(8):675-676. PubMed ID: 33577202
[TBL] [Abstract][Full Text] [Related]
24. Combined Early and Late [
Hohberg M; Kobe C; Täger P; Hammes J; Schmidt M; Dietlein F; Wild M; Heidenreich A; Drzezga A; Dietlein M
Mol Imaging Biol; 2019 Jun; 21(3):558-566. PubMed ID: 30105521
[TBL] [Abstract][Full Text] [Related]
25. Metastatic Prostate Carcinoma Presenting as a Superscan on 68Ga-PSMA PET/CT.
Lawal I; Vorster M; Boshomane T; Ololade K; Ebenhan T; Sathekge M
Clin Nucl Med; 2015 Sep; 40(9):755-6. PubMed ID: 26053729
[TBL] [Abstract][Full Text] [Related]
26. 68Ga-PSMA-11 PET/CT in Newly Diagnosed Prostate Adenocarcinoma.
Ergül N; Yilmaz Güneş B; Yücetaş U; Toktaş MG; Çermik TF
Clin Nucl Med; 2018 Dec; 43(12):e422-e427. PubMed ID: 30273204
[TBL] [Abstract][Full Text] [Related]
27. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients.
Schmidkonz C; Cordes M; Goetz TI; Prante O; Kuwert T; Ritt P; Uder M; Wullich B; Goebell P; Bäuerle T
Ann Nucl Med; 2019 Oct; 33(10):766-775. PubMed ID: 31338731
[TBL] [Abstract][Full Text] [Related]
28. Preliminary results on response assessment using
Seitz AK; Rauscher I; Haller B; Krönke M; Luther S; Heck MM; Horn T; Gschwend JE; Schwaiger M; Eiber M; Maurer T
Eur J Nucl Med Mol Imaging; 2018 Apr; 45(4):602-612. PubMed ID: 29185010
[TBL] [Abstract][Full Text] [Related]
29.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
30. Evidence of Prostate-Specific Membrane Antigen Expression in Metastatic Differentiated Thyroid Cancer Using 68Ga-PSMA-HBED-CC PET/CT.
Verma P; Malhotra G; Agrawal R; Sonavane S; Meshram V; Asopa RV
Clin Nucl Med; 2018 Aug; 43(8):e265-e268. PubMed ID: 29894335
[TBL] [Abstract][Full Text] [Related]
31.
Rischpler C; Beck TI; Okamoto S; Schlitter AM; Knorr K; Schwaiger M; Gschwend J; Maurer T; Meyer PT; Eiber M
J Nucl Med; 2018 Sep; 59(9):1406-1411. PubMed ID: 29371407
[TBL] [Abstract][Full Text] [Related]
32. Radiation dosimetry of (68)Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing.
Afshar-Oromieh A; Hetzheim H; Kübler W; Kratochwil C; Giesel FL; Hope TA; Eder M; Eisenhut M; Kopka K; Haberkorn U
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1611-20. PubMed ID: 27260521
[TBL] [Abstract][Full Text] [Related]
33. Synchronous Detection of Male Breast Cancer and Prostatic Cancer in a Patient With Suspected Prostatic Carcinoma on 68Ga-PSMA PET/CT Imaging.
Kumar R; Mittal BR; Bhattacharya A; Singh H; Singh SK
Clin Nucl Med; 2018 Jun; 43(6):431-432. PubMed ID: 29538032
[TBL] [Abstract][Full Text] [Related]
34.
Iravani A; Hofman MS; Mulcahy T; Williams S; Murphy D; Parameswaran BK; Hicks RJ
Cancer Imaging; 2017 Dec; 17(1):31. PubMed ID: 29268784
[TBL] [Abstract][Full Text] [Related]
35. Detection of recurrent prostate cancer lesions before salvage lymphadenectomy is more accurate with (68)Ga-PSMA-HBED-CC than with (18)F-Fluoroethylcholine PET/CT.
Pfister D; Porres D; Heidenreich A; Heidegger I; Knuechel R; Steib F; Behrendt FF; Verburg FA
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1410-7. PubMed ID: 26993315
[TBL] [Abstract][Full Text] [Related]
36. Incidental Metastatic Melanoma Identified on 68Ga-Prostate-Specific Membrane Antigen PET/CT for Metastatic Prostate Cancer.
Snow HA; Hofman MS; Mitchell CA; Gyorki DE; Smith MJF
Clin Nucl Med; 2018 Jul; 43(7):509-511. PubMed ID: 29742609
[TBL] [Abstract][Full Text] [Related]
37. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score.
Verburg FA; Pfister D; Heidenreich A; Vogg A; Drude NI; Vöö S; Mottaghy FM; Behrendt FF
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):397-403. PubMed ID: 26563121
[TBL] [Abstract][Full Text] [Related]
38. 18F-FDG, 68Ga-DOTATATE and 68Ga-PSMA Positive Metastatic Large Cell Neuroendocrine Prostate Tumor.
Acar E; Kaya GÇ
Clin Nucl Med; 2019 Jan; 44(1):53-54. PubMed ID: 30325820
[TBL] [Abstract][Full Text] [Related]
39. Incidental Detection of Thyroid Metastases From Renal Cell Carcinoma Using 68Ga-PSMA PET/CT to Assess Prostate Cancer Recurrence.
Zacho HD; Nielsen JB; Dettmann K; Haberkorn U; Petersen LJ
Clin Nucl Med; 2017 Mar; 42(3):221-222. PubMed ID: 28033223
[TBL] [Abstract][Full Text] [Related]
40. Pulmonary Opacities and Bronchiectasis Avid on 68Ga-PSMA PET.
Bouchelouche K; Vendelbo MH
Clin Nucl Med; 2017 Apr; 42(4):e216-e217. PubMed ID: 28134694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
